Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Diabetes and Ramadan: Practical guidelines 2021.
Hassanein M, Afandi B, Yakoob Ahmedani M, Mohammad Alamoudi R, Alawadi F, Bajaj HS, Basit A, Bennakhi A, El Sayed AA, Hamdy O, Hanif W, Jabbar A, Kleinebreil L, Lessan N, Shaltout I, Mohamad Wan Bebakar W, Abdelgadir E, Abdo S, Al Ozairi E, Al Saleh Y, Alarouj M, Ali T, Ali Almadani A, Helmy Assaad-Khalil S, Bashier AMK, Arifi Beshyah S, Buyukbese MA, Ahmad Chowdhury T, Norou Diop S, Samir Elbarbary N, Elhadd TA, Eliana F, Ezzat Faris M, Hafidh K, Hussein Z, Iraqi H, Kaplan W, Khan TS, Khunti K, Maher S, Malek R, Malik RA, Mohamed M, Sayed Kamel Mohamed M, Ahmed Mohamed N, Pathan S, Rashid F, Sahay RK, Taha Salih B, Sandid MA, Shaikh S, Slim I, Tayeb K, Mohd Yusof BN, Binte Zainudin S. Hassanein M, et al. Among authors: bajaj hs. Diabetes Res Clin Pract. 2022 Mar;185:109185. doi: 10.1016/j.diabres.2021.109185. Epub 2022 Jan 8. Diabetes Res Clin Pract. 2022. PMID: 35016991 Review.
Patient Reported Outcomes following initiation of Glucagon-like peptide-1 Receptor agonists in patients with type 2 Diabetes in a specialist endocrinology practice of the LMC diabetes registry: The PROGRESS-Diabetes study.
Brown RE, Abitbol A, Bajaj HS, Goldenberg R, Khandwala H, Abdel-Salam S, Aronson R. Brown RE, et al. Among authors: bajaj hs. Diabetes Res Clin Pract. 2019 Oct;156:107820. doi: 10.1016/j.diabres.2019.107820. Epub 2019 Aug 22. Diabetes Res Clin Pract. 2019. PMID: 31446111
Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial.
Pieber TR, Bajaj HS, Heller SR, Jia T, Khunti K, Klonoff DC, Ladelund S, Leiter LA, Wagner L, Philis-Tsimikas A. Pieber TR, et al. Among authors: bajaj hs. Diabetes Obes Metab. 2022 Feb;24(2):332-336. doi: 10.1111/dom.14564. Epub 2021 Oct 17. Diabetes Obes Metab. 2022. PMID: 34605127 Free PMC article. No abstract available.
Randomized Comparison of Initiating the Fixed-Ratio Combination of iGlarLixi or Biosimilar Insulin Glargine Together With Gliclazide in Participants of South Asian Origin With Type 2 Diabetes: VARIATION 2 SA Trial.
Bajaj HS, Chu L, Bansal N, Brown RE, Dhillon G, Gupta R, Bhela JS, Padda JK, Khandwala H, Venn K, Aronson R. Bajaj HS, et al. Can J Diabetes. 2022 Jul;46(5):495-502. doi: 10.1016/j.jcjd.2022.02.003. Epub 2022 Feb 11. Can J Diabetes. 2022. PMID: 35752566 Clinical Trial.
75 results